Search Results

Filter
  • 1-10 of  73 results for ""Cystadenocarcinoma, Serous""
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.

  • Authors : Shibahara M; Department of Obstetrics and Gynecology, Institute of Industrial Ecological Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan.; Kurita T

Subjects: Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/drug therapy ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/genetics ; Ovarian Neoplasms*/Ovarian Neoplasms*/Ovarian Neoplasms*/metabolism

  • Source: Anticancer research [Anticancer Res] 2023 Aug; Vol. 43 (8), pp. 3787-3792.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.

  • Authors : Lai J; Department of Pathology and Laboratory Medicine, Kaiser Permanente Sacramento Medical Center, Sacramento, CA, U.S.A.; .

Subjects: Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*genetics ; Fallopian Tube Neoplasms/Fallopian Tube Neoplasms/Fallopian Tube Neoplasms/*genetics ; HSP90 Heat-Shock Proteins/HSP90 Heat-Shock Proteins/HSP90 Heat-Shock Proteins/*genetics

  • Source: Anticancer research [Anticancer Res] 2021 Sep; Vol. 41 (9), pp. 4417-4422.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Mesonephric-like Differentiation of Ovarian Endometrioid and High-grade Serous Carcinomas: Clinicopathological and Molecular Characteristics Distinct from Those of Mesonephric-like Adenocarcinoma.

  • Authors : Choi KH; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Kim H

Subjects: Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*metabolism ; Carcinoma, Endometrioid/Carcinoma, Endometrioid/Carcinoma, Endometrioid/*pathology ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*pathology

  • Source: Anticancer research [Anticancer Res] 2021 Sep; Vol. 41 (9), pp. 4587-4601.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Up-regulation of HDAC6 Results in Poor Prognosis and Chemoresistance in Patients With Advanced Ovarian High-grade Serous Carcinoma.

  • Authors : Yano M; Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.; Department of Obstetrics and Gynaecology, Oita University Faculty of Medicine, Oita, Japan.

Subjects: Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*drug therapy ; Histone Deacetylase 6/Histone Deacetylase 6/Histone Deacetylase 6/*physiology ; Ovarian Neoplasms/Ovarian Neoplasms/Ovarian Neoplasms/*drug therapy

  • Source: Anticancer research [Anticancer Res] 2021 Mar; Vol. 41 (3), pp. 1647-1654.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Prominent Papillary Growth Pattern and Severe Nuclear Pleomorphism Induced by Neoadjuvant Chemotherapy in Ovarian Mucinous Carcinoma: Potential for Misdiagnosis as High-grade Serous Carcinoma.

  • Authors : Kwon HJ; Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.; Song SY

Subjects: Adenocarcinoma, Mucinous/Adenocarcinoma, Mucinous/Adenocarcinoma, Mucinous/*drug therapy ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*pathology ; Ovarian Neoplasms/Ovarian Neoplasms/Ovarian Neoplasms/*drug therapy

  • Source: Anticancer research [Anticancer Res] 2021 Mar; Vol. 41 (3), pp. 1579-1586.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

WNT Signaling Driven by R-spondin 1 and LGR6 in High-grade Serous Ovarian Cancer.

  • Authors : Lee S; Department of Obstetrics and Gynecology, Korea University College of Medicine, Seoul, Republic of Korea.; Jun J

Subjects: Wnt Signaling Pathway*/Wnt Signaling Pathway*/Wnt Signaling Pathway*/genetics; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*metabolism ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*pathology

  • Source: Anticancer research [Anticancer Res] 2020 Nov; Vol. 40 (11), pp. 6017-6028.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.

  • Authors : Jung YY; Department of Pathology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Republic of Korea.; Woo HY

Subjects: Sequence Deletion* ; Up-Regulation*; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*surgery

  • Source: Anticancer research [Anticancer Res] 2019 Jun; Vol. 39 (6), pp. 2883-2889.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of miR34a and miR200 .

Subjects: B7-H1 Antigen/B7-H1 Antigen/B7-H1 Antigen/*blood ; Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*blood ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*blood

  • Source: Anticancer research [Anticancer Res] 2018 Oct; Vol. 38 (10), pp. 5739-5745.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.

  • Authors : Parashkevova A; Ovarian Cancer Tumor Bank, Virchow Campus Clinic, Charité Medical University, Berlin, Germany.; Sehouli J

Subjects: Biomarkers, Tumor/Biomarkers, Tumor/Biomarkers, Tumor/*blood ; CA-125 Antigen/CA-125 Antigen/CA-125 Antigen/*blood ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*pathology

  • Source: Anticancer research [Anticancer Res] 2018 Aug; Vol. 38 (8), pp. 4865-4870.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
Academic Journal

Surgical Outcomes and Morbidity After Radical Surgery for Ovarian Cancer in Aberdeen Royal Infirmary, the Northeast of Scotland Gynaecologic Oncology Centre.

  • Authors : Kalampokas E; Department of Gynecologic Oncology, Aberdeen Royal Infirmary, Aberdeen, U.K. .; Young H

Subjects: Adenocarcinoma, Clear Cell/Adenocarcinoma, Clear Cell/Adenocarcinoma, Clear Cell/*surgery ; Adenocarcinoma, Mucinous/Adenocarcinoma, Mucinous/Adenocarcinoma, Mucinous/*surgery ; Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/Cystadenocarcinoma, Serous/*surgery

  • Source: Anticancer research [Anticancer Res] 2018 Feb; Vol. 38 (2), pp. 923-928.Publisher: International Institute of Anticancer Research Country of Publication: Greece NLM ID: 8102988 Publication Model:

Record details

×
  • 1-10 of  73 results for ""Cystadenocarcinoma, Serous""